IL-8/CXCL8 Upregulates 12-Lipoxygenase Expression in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

Jung Hae Kim1, Young Jin Kang2 and Hee Sun Kim1*
Departments of 1Microbiology, 2Pharmacology and Aging-associated Vascular Disease Research Center, College of Medicine, Yeungnam University, Daegu, Korea

Background: We previously demonstrated remarkable differences in the expression of IL-8/CXCL8 in aortic tissues and vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR) compared to VSMC from normotensive Wistar-Kyoto rats (WKY). In the present study, we investigated the direct effect of IL-8/CXCL8 on expression of 12-lipoxygenase (LO), a hypertensive modulator, in SHR VSMC. Methods: Cultured aortic VSMC from SHR and WKY were used. Expression of 12-LO mRNA was determined by real-time polymerase chain reaction. Phosphorylation of ERK1/2 and production of 12-LO and angiotensin II subtype 1 (AT1) receptor were assessed by Western blots. IL-8/CXCL8-stimulated DNA synthesis was determined by measuring incorporation of [3H]-thymidine. And effect of IL-8/CXCL8 on vascular tone was determined by phenylephrine-induced contraction of thoracic aortic rings. Results: Treatment with IL-8/CXCL8 greatly increased 12-LO mRNA expression and protein production compared to treatment with angiotensin II. IL-8/CXCL8 also increased the expression of the AT1 receptor. The increase in 12-LO induced by IL-8/CXCL8 was inhibited by treatment with an AT1 receptor antagonist. The induction of 12-LO mRNA production and the proliferation of SHR VSMC by IL-8/CXCL8 was mediated by the ERK pathway. The proliferation of SHR VSMC and the vascular contraction in the thoracic aortic ring, both of which were induced by IL-8/CXCL8, were inhibited by baicalein, a 12-LO inhibitor. Conclusion: These results suggest that the potential role of IL-8/CXCL8 in hypertensive processes is likely mediated through the 12-LO pathway.

INTRODUCTION

Controlling chemokine production is important for regulating inflammatory reactions in hypertensive vascular walls. Inflammatory cell infiltration and oxidative stress in vascular walls contribute to the pathogenesis of hypertension, and the suppression of inflammatory cell infiltration has been shown to ameliorate hypertension in experimental animal models (1-5). The chemokine IL-8/CXCL8 has been known to play an important role in monocyte migration into the subendothelial space in the early phase of atherosclerosis. In addition, elevated levels of IL-8/CXCL8 are associated with an increased risk of future coronary artery disease (6,7). We have previously demonstrated that the expression of IL-8/CXCL8 in aortic tissue and in vascular VSMC in SHR was higher than in VSMC from normotensive WKY (8).

IL-8/CXCL8 was shown to increase 12-lipoxygenase (12-LO) mRNA expression and protein production in porcine aortic VSMC (9). The 12-LO pathway of arachidonic acid metabolism has been linked to cell growth and to the pathology of hypertension (10-12). Angiotensin II (Ang II) is a potent positive regulator of 12-LO activation and expression in porcine and human VSMC (13,14). Increased levels of 12-LO induced by cytokines in porcine VSMC and an elevated level of 12-LO activity in SHR plasma have been reported (9,15). However, neither the mechanism of IL-8/CXCL8 induction of 12-LO expression nor the association between IL-8/CXCL8 and the 12-LO pathway specific to SHR VSMC have been studied. Therefore, we investigated the mechanism of action of...
IL-8/CXCL8 in relation to the expression of 12-LO in SHR VSMC.

MATERIALS AND METHODS

Reagents
The Trizol reagent for total RNA isolation was purchased from Invitrogen (Carlsbad, CA), PBS, DMEM, penicillin-streptomycin and FBS were purchased from Gibco/BRL (Life Technologies, Gaithersburg, MD). Recombinant human IL-8/CXCL8 was purchased from R&D systems (Minneapolis, MN). Baicalein was obtained from Sigma Chemical Co. (St Louis, MO). Ang II was obtained from Calbiochem (San Diego, CA). 12-Hydroxyeicosatetraenoic acid (12-HETE) was purchased from Cayman Chemical (Ann Arbor, MI). Losartan was obtained from MSD (Delaware, MD). MAPK inhibitor and 2'-amino-3'-methoxyflavone (PD08059) were purchased from Calbiochem, Nitrocellulose transfer membranes were obtained from Schleicher & Schuell Bioscience (Dassel, Germany). Oligonucleotide primers for PCR of 12-LO, the AT1 receptor, the AT2 receptor and β-actin were synthesized with Bionics (Seoul, Korea). LightCycler FastStart DNA SYBR Green I Mix was obtained from Roche (Mannheim, Germany). The 12-LO antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The AT1 receptor antibody was purchased from Abcam (Cambridge, UK). The phospho-ERK antibody was obtained from Cell Signaling Technology (Danvers). The g-tubulin antibody was obtained from Sigma Chemical Co. (St Louis, MO). All other reagents were from pure-grade commercial preparations.

Experimental animals
Specific pathogen-free male inbred WKY and SHR, 20 to 30 weeks of age, were purchased from Japan SLC Inc. (Shizuoka, Japan). All experimental animals received autoclaved food and bedding to minimize exposure to viral and microbial pathogens. The rats were cared for in accordance with the Guide for the Care and Use of Experimental Animals of Yeungnam Medical Center.

VSMC preparation
VSMC were obtained by an explant method from the thoracic aortas of 20- to 30-week-old male SHR and WKY as described by Kim et al. (8). VSMC were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were detached with 0.25% trypsin/EDTA and seeded into 75-cm² tissue culture flasks at a density of 10⁵ cells per milliliter. All experiments were conducted during cell passages 3 to 7. Prior to stimulation, 95% confluent VSMC were serum-starved overnight by incubating in DMEM with 0.1% FBS. Cell cultures were incubated in a humidified incubator at 37°C and 5% CO₂ in the presence or absence of stimuli for the indicated times.

Preparation of total RNA and real-time PCR
Total RNA was extracted using the Trizol reagent according to the manufacturer’s instructions. The quantity of total RNA obtained was determined by measuring the optical density (OD) at 260 and 280 nm. Real-time PCR amplification of 12-LO, the AT1 receptor and the AT2 receptor from VSMC was performed using a LightCycler (Roche, Germany). cDNA was obtained by reverse transcription using 1 μg of total RNA and then subjected to real-time PCR. PCR was performed in triplicate. Each 20-μl reaction contained LightCycler FastStart DNA SYBR Green I mix (Roche, Germany), primer and 2 μl of cDNA. Prior to PCR amplification, the mixture was incubated at 95°C for 10 min. The amplification consisted of 45 cycles of denaturation (10 s at 95°C), annealing (5 s at the primer-appropriate temperature), and extension (10 s at 72°C) with fluorescence detection at 72°C after each cycle. After the final cycle, melting point analysis of each sample was performed over the range of 65 to 95°C with continuous fluorescence detection. Expression levels of β-actin were used for sample normalization. The results for each gene are expressed as the expression level relative to the expression level of β-actin. The primers used for PCR were as follows: 12-LO (512 bp) sense, 5'-agggcactggagag-3', antisense, 5'-agagacctgacccatc-3'; AT1 receptor (445 bp) sense, 5'-cactcagatgacgctg-3', antisense, 5'-gacratcgccataatctc-3'; AT2 receptor (65 bp) sense, 5'-cggccacagctgctcaagt-3', antisense, 5'-agagctgacccatc-3'; β-actin (101 bp) sense, 5'-tcaggggtcctagca-3', antisense, 5'-ttactgctgctcagca-3'. The levels of 12-LO, AT1 receptor and AT2 receptor mRNA were determined by comparing experimental levels to standard curves. mRNA levels were expressed as the fold increase or decrease of expression.

Western blotting
Total lysates were prepared in PRO-PREP buffer (iNtRON, Seoul, Korea). Protein concentrations were determined by a Bradford assay (Bio-Rad, CA) using bovine serum albumin as a standard. Thirty micrograms of the protein samples were
Upregulation of 12-lipoxygenase by IL-8/CXCL8  
Jung Hae Kim, et al.

108 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 3 June 2009

separated on 10% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes. The membranes were soaked in 5% nonfat dried milk in TBST (10 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl and 0.05% Tween-20) for 1 h and then incubated for 16~18 h at 4°C with primary antibodies against 12-LO, the AT1 receptor, phospho-ERK and γ-tubulin. The membranes were washed three times with TBST for 10 min and then incubated with HRP-conjugated secondary antibody for 1 h at 4°C. The membranes were rinsed three times with TBST for 10 min, and antigen-antibody complexes were detected using an enhanced chemiluminescence detection system (LAS-3000; Fujifilm, Tokyo, Japan).

VSMC proliferation
VSMC were plated in 24-well plates for 24 h and then exposed to the stimulant, [3H]-thymidine (1 μCi/ml) (Perkin-Elmer, Boston, MA) was added to the plates during the final 48 h of incubation. The cells were subsequently washed three times with cold PBS, [3H]-thymidine-labeled cells were collected with 0.1% SDS, and radioactivity was measured using a Packard scintillation counter (Packard instrument company, Meriden).

Measurement of vascular tone
The thoracic aorta was cleared of adherent periadventitial fat and cut into rings 3~4 mm in width. To assess the direct effects of IL-8/CXCL8 on the vascular smooth muscle, the endothelium was removed by gently rubbing the luminal surface with a needle. The rings were mounted in an organ bath filled with Krebs solution (pH 7.4: in mmol/L: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 5.7 glucose, 25 NaHCO3) at 37°C and 95% O2-5% CO2. Isometric force was measured with a force transducer (FT03, Grass Instrument). A tension of 1 g was applied, and the rings were equilibrated for 60 min. During this process, the Krebs solution was changed every 15 min. The rings were then challenged with phenylephrine (PE, 10 μmol/L) to ensure tissue viability and with acetylcholine (Ach, 10 μmol/L) to ensure the absence of an endothelium. After inducing maximal contraction with the PE challenge, the vessels were incubated with IL-8/CXCL8.
Upregulation of 12-lipoxygenase by IL-8/CXCL8
Jung Hae Kim, et al.

IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 3 June 2009

(200 ng/ml) and baicalein (10 μmol/L) for 1 h. After incubation with IL-8/CXCL8 and baicalein, a cumulative phenylephrine dose-response curve was constructed (1~100 μmol/L).

Statistical analysis
The results are expressed as the mean±SD of at least three independent experiments. For comparisons among multiple groups, statistical significance was determined using the Mann-Whitney test using SPSS version 12.0.

RESULTS

Effect of IL-8/CXCL8 on 12-LO in SHR VSMC
We compared 12-LO expression in both SHR VSMC with the expression in and WKY VSMC. Expression of 12-LO mRNA was found to be higher in SHR VSMC relative to WKY VSMC (Fig. 1A). In addition, IL-8/CXCL8 treatment did not increase the expression level of 12-LO mRNA in WKY VSMC (Fig. 1B). We next examined the expression of 12-LO in SHR VSMC that had been treated with IL-8/CXCL8. In contrast, IL-8/CXCL8 treatment in SHR VSMC greatly induced the expression of 12-LO mRNA compared to Ang II treatment (Fig. 1C). Large amounts of 12-LO protein were detected in SHR VSMC that had been treated with IL-8/CXCL8 for 4 h (Fig. 1D).

Effect of the AT1 receptor on IL-8/CXCL8-induced 12-LO expression in SHR VSMC
To determine whether IL-8/CXCL8-induced 12-LO production is mediated by the AT1 receptor, we first examined the effect of IL-8/CXCL8 on AT1 and AT2 receptor mRNA expression in WKY and SHR VSMC. IL-8/CXCL8 did not increase the expression of AT1 or AT2 receptor mRNA in WKY VSMC (Fig. 2A). However, treatment with IL-8/CXCL8 increased the expression of AT1 receptor mRNA in SHR VSMC (Fig. 2A). AT1

![Figure 2](image-url)

**Figure 2.** IL-8/CXCL8 increases AT1 receptor expression in SHR VSMC, and IL-8/CXCL8-induced expression of 12-LO mRNA is mediated through the AT1 receptor. (A) WKY and SHR VSMC were untreated or treated with IL-8/CXCL8 (100 ng/ml) for 2 h, and total RNA was analyzed by real-time PCR. Bars represent mean±SD from four independent experiments. *p<0.05 vs. untreated VSMC. (B) VSMC were untreated or treated with IL-8/CXCL8 (100 ng/ml) for 2 and 4 h. Cell lysates were separated on 10% SDS-polyacrylamide gels and then immunoblotted with the AT1 receptor antibody. Data shown are representative of three independent experiments. (C) VSMC were untreated or treated with IL-8/CXCL8 (100 ng/ml) or IL-8/CXCL8 plus losartan (AT1 receptor antagonist, 10 μmol/L) for 2 h or 4 h, and the total RNA and cell lysates were isolated. Total RNA was analyzed by real-time PCR. Cell lysates were separated on 10% SDS-polyacrylamide gels and then immunoblotted with the 12-LO antibody. Bars represent mean±SD from three independent experiments. *p<0.05 vs. VSMC treated with IL-8/CXCL8. Data shown are representative of three independent experiments.
Upregulation of 12-lipoxygenase by IL-8/CXCL8
Jung Hae Kim, et al.

**Figure 3.** Expression of IL-8/CXCL8-induced 12-LO is mediated through the ERK pathway, and proliferation of SHR VSMC by IL-8/CXCL8 is inhibited by baicalein and PD98059. (A, B) VSMC were untreated (NT) or pretreated with PD98059 (ERK inhibitor, 10 μmol/L) for 30 min. Cells were left untreated or treated with IL-8/CXCL8 (100 ng/ml) for 2 h, and the total RNA and cell lysates were isolated. The total RNA was analyzed by real-time PCR (A), and cell lysates were separated on 10% SDS-polyacrylamide gels and then immunoblotted with the phospho-ERK1/2 antibody (B). Bars represent means ± SD of three independent experiments. a: p < 0.05 vs. control rings. b: p < 0.05 vs. control rings. c: p < 0.05 vs. control rings. d: p < 0.05 vs. untreated VSMC. (C, D) SHR VSMC were treated with 12-HETE (500 nmol/L), with IL-8/CXCL8 (100 ng/ml), with baicalein (12-LO inhibitor, 10 μmol/L, B), or with PD98059 (10 μmol/L, C) for 48 h in medium containing [3H]-thymidine (1 μCi/ml). [3H]-thymidine incorporation is shown on the Y-axis. Bars represent means ± SD from three independent experiments run in triplicate. *p < 0.05 vs. untreated VSMC. **p < 0.01 vs. VSMC treated with IL-8/CXCL8 alone. a: p < 0.05 vs. untreated VSMC. **p < 0.01 vs. VSMC treated with IL-8/CXCL8 alone.

Figure 4. Effect of IL-8/CXCL8 on the phenylephrine-induced contraction of thoracic aortic rings. Phenylephrine (1–100 μmol/L) was added to isolated thoracic aortic rings pretreated with IL-8/CXCL8 (200 ng/ml) and/or the 12-LO inhibitor baicalein (10 μmol/L) for 1 h. All contractions are expressed as grams (g) of contractile tension in control rings not exposed to IL-8/CXCL8 or baicalein. Data are means ± SD of three independent experiments. a: p < 0.05 vs. control rings. b: p < 0.05 vs. rings treated with IL-8/CXCL8 alone.

**Figure 2B.** The AT1 receptor antagonist losartan (10 μmol/L) was found to significantly inhibit IL-8/CXCL8-induced expression of 12-LO mRNA. The production of the 12-LO protein was also inhibited by this antagonist (Fig. 2C). These results suggest that the induction of 12-LO expression by IL-8/CXCL8 is mediated through the AT1 receptor expression in SHR VSMC.

**IL-8/CXCL8-induced 12-LO expression is mediated by ERK phosphorylation**

We investigated whether the MAPK signaling pathway is involved in IL-8/CXCL8-induced 12-LO expression. The IL-8/CXCL8-induced expression of 12-LO mRNA was decreased by PD98059 (Fig. 3A), and a high level of phosphorylation of ERK in SHR VSMC treated with IL-8/CXCL8 was detected (Fig. 3B).
Effect of 12-LO and ERK activation on IL-8/CXCL8-induced VSMC proliferation

It has been reported that IL-8/CXCL8 induces rat and human VSMC proliferation (16). Having established that IL-8/CXCL8 enhances 12-LO expression and stimulates VSMC proliferation, we evaluated the effect of 12-HETE, the product of 12-LO catalysis, on SHR VSMC proliferation. Fig. 3C shows that 12-HETE directly stimulates VSMC proliferation. In addition, baicalein, which is an inhibitor of 12-LO, significantly inhibited the IL-8/CXCL8-induced proliferation of SHR VSMC. IL-8/CXCL8-induced SHR VSMC proliferation was also completely blocked by PD98059 (Fig. 3D). These results suggest that ERK and 12-LO are linked in the IL-8/CXCL8-induced SHR VSMC proliferation pathway.

Effect of 12-LO on IL-8/CXCL8-induced vascular tone contraction

We also examined the potential role of 12-LO in mediating the vascular contraction effects of IL-8/CXCL8. This was done by assessing the effect of 10 μmol/L baicalein on IL-8/CXCL8-induced vascular contractions. The endothelium of the aortic rings was removed to determine the direct effect of IL-8/CXCL8 on vascular smooth muscle. The force of vascular contractions induced by IL-8/CXCL8 was generated greater than those of the control group. However, baicalein considerably inhibited the contraction-inducing effect of IL-8/CXCL8 (Fig. 4).

DISCUSSION

AT1 receptor mediates most of pathophysiological actions of Ang II. Whereas stimulation of the AT1 receptor leads to activate cytokines and adhesion molecules expression, cell growth, angiogenesis and vasoconstriction, AT1 receptor stimulation causes opposite effects, including apoptosis, anti-angiogenesis, and vasodilatation (17-19). AT1 receptor is widely expressed in all organs and, especially, VSMC expresses AT1 receptors at ordinary times (20,21). In our study, we detected the expression of AT1 receptor mRNA in VSMC both of from SHR and WKY, however, the protein production of AT1 receptor was very weak in SHR VSMC (Fig. 1). IL-8/CXCL8 increased AT1 receptor mRNA expression in SHR VSMC only, and confirmed strong production of AT1 receptor protein (Fig. 2B). Therefore, we observed the effects of AT1 receptor antagonists on IL-8/CXCL8-induced 12-LO production in SHR VSMC, AT1 receptor antagonist significantly inhibited IL-8/CXCL8-induced 12-LO production (Fig. 2C). These results suggest that the action of IL-8/CXCL8 on hypertensive vasculature is likely to be associated with the AT1 receptor.

ERK pathway was involved in IL-8/CXCL8-induced 12-LO expression in SHR VSMC. The IL-8/CXCL8-induced expression of 12-LO mRNA was decreased remarkably by PD98059, an inhibitor of ERK (Fig. 3A). We also examined whether p38 signaling pathway is involved in IL-8/CXCL8-induced 12-LO expression in SHR VSMC. PD169316, an inhibitor of p38, also decreased the expression of IL-8/CXCL8-induced 12-LO mRNA in SHR VSMC. However, it did not inhibit significantly IL-8/CXCL8-induced 12-LO mRNA expression compared to PD98059 (data not shown).

IL-8/CXCL8 has been shown to have mitogenic effects on VSMC (16), and Natarajan et al. (9) reported that 12-LO inhibition decreased IL-8/CXCL8-induced proliferation in porcine VSMC. We also found that baicalein inhibited IL-8/CXCL8-induced proliferation of SHR VSMC and that SHR VSMC proliferation induced by IL-8/CXCL8 was greater than Ang II-induced proliferation (data not shown). ERK activation has been demonstrated in the normal growth of mesangial cells and pulmonary artery smooth muscle cells in association with the stimulation of the 12-LO pathway (10,22). In this study, IL-8/CXCL8-induced 12-LO expression was mediated through ERK activation. In addition, IL-8/CXCL8-induced VSMC proliferation was completely blocked by PD98059. These results suggest that ERK activation and 12-LO expression are linked in IL-8/CXCL8-induced VSMC proliferation and that 12-LO induction precedes ERK activation.

Buemi et al. (23) suggested that IL-8/CXCL8 may directly enhance membrane permeability to Ca²⁺, thus inducing vasoconstriction in the smooth muscle cells of patients with essential hypertension. However, Ohkawa et al. (24) reported that IL-8/CXCL8 had no significant effect on the vascular contraction of the thoracic aorta in Sprague-Dawley rats. In the present study, we observed a significant increase in the contraction of the thoracic aorta rings from SHR that were treated with IL-8/CXCL8, and this contraction decreased after baicalein treatment (Fig. 4). This result suggests that IL-8/CXCL8 acts on vascular contraction through the 12-LO pathway in SHR.

This study demonstrates that IL-8/CXCL8-induced 12-LO expression is mediated through the AT1 receptor in SHR VSMC and that the 12-LO pathway participates in IL-8/CXCL8-induced contraction.
SHR VSMC proliferation, most likely via the ERK pathway. Taken together, our results suggest that the effect of IL-8/CXCL8 on hypertensive vascular walls is mediated by the induction of the 12-LO pathway.

ACKNOWLEDGEMENTS

This study was supported by the Korean Science and Engineering Foundation through the Aging-associated Vascular Disease Research Center at Yeungnam University [R13-2005-005-02002-0(2007)].

CONFLICTS OF INTEREST

The authors have no financial conflict of interest.

REFERENCES

1. Alexander RW: Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 25:155-161, 1995
2. Capers Q 4th, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR: Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats, Hypertension 30:1397-1402, 1997
3. Zhang Y, Griendling KK, Dikalova A, Owens GK, Talyor WR: Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 46:732-737, 2005
4. Rodriguez-Iiturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ: Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all, Am J Physiol 286:F606-F616, 2004
5. Dhuniana S, Sharack B, Woodroffe N: Cytokines and chemokines in idiopathic intracranial hypertension, Headache 49:282-285, 2009
6. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding MA, Gimbrone MA, Luster AD, Lusinskas FW, Rosenzweig A: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions, Nature 398;718-723, 1999
7. Boekholdt S, Peters R, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT: IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women, Arterioscler Thromb Vasc Biol 24:1503-1508, 2004
8. Kim HY, Kang YJ, Song IH, Choi HC, Kim HS: Upregulation of IL-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats, Hypertens Res 31:515-523, 2008
9. Natarajan R, Rosdahl J, Gonzales N, Bai W: Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells, Hypertension 30:873-879, 1997
10. Preston IR, Hill NS, Warburton RR, Fanburg BL: Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation, Am J Lung Cell Mol Physiol 2003;507-517, 2006
11. Merced AJ, Ko K, Gotlinger KH, Serhan CN, Chan L: Atherosclerosis: evidence for resolution of vascular inflammation governed by specific lipid mediators, FASEB J 22:3595-3606, 2008
12. Reddy MA, Sahar S, Villeneuve LM, Lanting L, Natanaraj R: Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells, Arterioscler Thromb Vasc Biol 29;387-393, 2009
13. Natarajan R, Gu JL, Rossi J, Gonzales N, Lanting L, Xu L, Nadler J: Elevated glucose angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells, Proc Natl Acad Sci USA 90:4947-4951, 1993
14. Kim JA, Gu JL, Natanaraj R, Berliner JA, Nadler JL: A leukocyte type 12-lipoxygenase is expressed in human vascular and mononuclear cells: Evidence for upregulation by angiotensin II, Arterioscler Thromb Vasc Biol 15;942-948, 1995
15. Sasaki M, Hori MT, Hino T, Golub MS, Tuck ML: Elevated 12-lipoxygenase activity in the spontaneously hypertensive rat, Am J Hypertens 10;371-378, 1997
16. Yue TL, Wang X, Sun QP: Interleukin-8: a mitogen and chemotactant for vascular smooth muscle cells, Circ Res 75;1-7, 1994
17. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsushima K, Takeshita A: Important role of local angiotensin II activity mediated via type I receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats, Circulation 101;305-310, 2000
18. Wolf G, Wenzel U, Burns KD, Harris BC, Stahl AK, Thaiss RJ: Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all, Am J Physiol 286:F606-F616, 2004
19. Siragy HM: AT1 and AT2 receptors in the kidney: Role of disease and treatment, Am J Kidney Dis 36(Suppl 1);S4-S9, 2000
20. Horiiuchi M, Akihita M, Dzau VJ: Recent progress in angiotensin II Type 2 receptor research in the cardiovascular system, Hypertension 33;613-621, 1999
21. Jin XQ, Fukushima N, Lai YM, Suzuki R, Tahira Y, Takgi H, Ikeda Y, Kamatsume K, Miyazaki E: Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells, Hypertension 39;1021-1027, 2002
22. Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW, Nadler JL, Shahed A, Natanaraj R: Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells, Am J Physiol Renal Physiol 285;F985-F994, 2003
23. Buerm M, Marino D, Floccari F, Ruell A, Nostro L, Aloisi C, Marino MT, Pasquale G, Corica F: Effect of interleukin 8 and ICAM-1 on calcium-dependent outflow of K+ in eryth-
rocytes from subjects with essential hypertension, Curr Med Res Opin 20:19-24, 2004
24. Ohkawa F, Ikeda U, T Kanbe, Kawasaki K, Shimada K:
Effects of inflammatory cytokines on vascular tone, Cardiovasc Res 30:711-715, 1995